Breast CarePub Date : 2021-12-01DOI: 10.1159/000521177
{"title":"PharmaNews","authors":"","doi":"10.1159/000521177","DOIUrl":"https://doi.org/10.1159/000521177","url":null,"abstract":"Im Kampf gegen Krebs nehmen biotechnologisch hergestellte Arzneimittel an Bedeutung zu. Der Anteil von Biopharmazeutika in der Onkologie stieg im ver gangenen Jahr auf 43% (2019: 41%), so der aktuelle Branchenreport der In teressengruppe Biotechnologie im Verband der forschenden PharmaUnter nehmen (vfa). Dieser Trend wird sich voraussichtlich auch in den nächsten Jahren fortsetzen, denn der Schwerpunkt der biotechnologischen Forschung liegt auf der Onkologie: 286 Forschungsprojekte, das sind 39% der Wirkstoff pipeline, suchen aktuell nach neuen Therapieansätzen gegen Krebs [1]. «Die Daten zeigen nicht nur den besonderen Stellenwert von Biopharmazeutika im Kampf gegen Krebs, sie sind auch ein Beleg für sehr hohe und kontinuierliche Investitionen in die biotechnologische Krebsforschung», sagt Manfred Heinzer, Geschäftsführer der Amgen GmbH. Rund ein Drittel der in Deutschland zuge lassenen 339 Biopharmazeutika nutzen laut vfaBiotechReport rekombinante Antikörper als Wirkstoff. 1998 wurde der erste biotechnologisch hergestellte Antikörper zugelassen, heute basieren 107 Arzneimittel auf dieser Wirkstoff klasse und die Pipeline ist gut gefüllt [1]. Ein wesentliches Anwendungsgebiet ist die Krebstherapie.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"16 1","pages":"683 - 684"},"PeriodicalIF":2.1,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43704298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2021-12-01DOI: 10.1159/000521407
B. Gulluoglu, S. Corradini
{"title":"Front & Back Matter","authors":"B. Gulluoglu, S. Corradini","doi":"10.1159/000521407","DOIUrl":"https://doi.org/10.1159/000521407","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46436423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2021-10-01DOI: 10.1159/000520067
B. Gulluoglu, S. Corradini
{"title":"Front & Back Matter","authors":"B. Gulluoglu, S. Corradini","doi":"10.1159/000520067","DOIUrl":"https://doi.org/10.1159/000520067","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48876847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2021-08-20DOI: 10.1159/000518260
Yi Zhang, Miao Liu, Houpu Yang, Shu Wang
{"title":"Physicians’ Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer","authors":"Yi Zhang, Miao Liu, Houpu Yang, Shu Wang","doi":"10.1159/000518260","DOIUrl":"https://doi.org/10.1159/000518260","url":null,"abstract":"Objective: To investigate physicians’ perception of the evidence of clinical trials on breast cancer. Methods: A survey was conducted by the Chinese Society of Breast Surgeons. We investigated the physicians’ perception of meaningful endpoints, appropriate follow-up duration, and clinically acceptable benefit through online questionnaires. Results: Among 278 validated questionnaires, the majority of the questions had no consistent answer. For local treatment, 30.6, 28.8, and 28.4% of participants regarded locoregional recurrence (LRR), disease-free survival (DFS), and overall survival (OS) as the most meaningful endpoint, respectively, 47.5% believed that 5-year follow-up can alter clinical practice, and 34.5% thought it should be >10 years. In the adjuvant setting, 45.7, 38.5, and 12.9% regarded DFS, OS, and LRR as the most meaningful endpoint, respectively, 52.5% thought that 10-year follow-up was solid, while 37.4% thought that 5-year follow-up was enough. In the advanced setting, 49.6, 24.1, and 23.7% considered progression-free survival, quality of life, and OS the most meaningful endpoint, respectively, and 39.6 and 28.8% considered that a follow-up of 1 year and 3 years, respectively, was meaningful. Similarly, the clinically acceptable absolute difference was inconsistent. Conclusion: Most Chinese oncologists advocated that surrogate endpoints could be used in certain circumstances, though OS was the most reliable one in breast cancer studies. Doctors’ perceptions of follow-up time and magnitude of benefit vary widely, reflecting the fact that there are many unanswered questions about supporting the use of new cancer treatments; a common understanding needs to be reached, such as a very consensual surrogate endpoint and a meaningful sufficiently large therapeutic benefit.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"180 - 187"},"PeriodicalIF":2.1,"publicationDate":"2021-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45190843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2021-08-12DOI: 10.1159/000517182
R. Schmutzler, Björn Schmitz-Luhn, B. Borisch, P. Devilee, D. Eccles, P. Hall, J. Balmaña, S. Boccia, P. Dabrock, G. Emons, W. Gaissmaier, J. Gronwald, S. Houwaart, S. Huster, K. Kast, A. Katalinic, S. Linn, S. Moorthie, P. Pharoah, K. Rhiem, T. Spranger, D. Stoppa-Lyonnet, J. V. van Delden, M. Van den Bulcke, C. Woopen
{"title":"Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors","authors":"R. Schmutzler, Björn Schmitz-Luhn, B. Borisch, P. Devilee, D. Eccles, P. Hall, J. Balmaña, S. Boccia, P. Dabrock, G. Emons, W. Gaissmaier, J. Gronwald, S. Houwaart, S. Huster, K. Kast, A. Katalinic, S. Linn, S. Moorthie, P. Pharoah, K. Rhiem, T. Spranger, D. Stoppa-Lyonnet, J. V. van Delden, M. Van den Bulcke, C. Woopen","doi":"10.1159/000517182","DOIUrl":"https://doi.org/10.1159/000517182","url":null,"abstract":"Background: Risk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action. Summary: Therefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"208 - 223"},"PeriodicalIF":2.1,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46321367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2021-08-01DOI: 10.1159/000518907
{"title":"PharmaNews","authors":"","doi":"10.1159/000518907","DOIUrl":"https://doi.org/10.1159/000518907","url":null,"abstract":"Das biologische Tumorprofil nimmt in der Behandlung des Mammakarzinoms eine entscheidende Rolle ein: Es ist ein zentraler Faktor bei der Therapiewahl – und beeinflusst maßgeblich die Prognose der Patientinnen. Während beispielsweise beim HER2-positiven Mammakarzinom die Prognose durch die Entwicklung perso-nalisierter Behandlungsstrategien wie Perjeta® (Pertuzumab), Kadcyla® (Trastuzumab-Emtansin) oder das jüngst zugelassene Kombinationspräparat Phesgo® enorm verbessert wurde, gilt das TNBC nach wie vor als ein schwer zu behandelnder Subtyp mit äußerst ungünstiger Prognose [1]. Einen bedeutsamen Fortschritt in der Behandlung des TNBC bietet die Krebsimmuntherapie mit Tecentriq (Atezolizumab) – bislang ist der PD-L1-Inhibitor in Kombination mit nab-Paclitaxel aber nur im fortgeschrittenen Krankheitsstadium zugelassen [2]. * pCR = pathologische Komplettremission.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"16 1","pages":"433 - 434"},"PeriodicalIF":2.1,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47698107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2021-08-01DOI: 10.1159/000519184
B. Gulluoglu, V. Hanf
{"title":"Front & Back Matter","authors":"B. Gulluoglu, V. Hanf","doi":"10.1159/000519184","DOIUrl":"https://doi.org/10.1159/000519184","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46336477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast CarePub Date : 2021-07-19DOI: 10.1159/000516376
K. Rhiem, B. Auber, S. Briest, N. Dikow, N. Ditsch, Neda Dragicevic, S. Grill, E. Hahnen, J. Horváth, B. Jaeger, K. Kast, M. Kiechle, E. Leinert, S. Morlot, M. Püsken, Dieter Schäfer, S. Schott, C. Schroeder, U. Siebers-Renelt, C. Solbach, N. Weber-Lassalle, I. Witzel, C. Zeder-Göss, R. Schmutzler
{"title":"Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer","authors":"K. Rhiem, B. Auber, S. Briest, N. Dikow, N. Ditsch, Neda Dragicevic, S. Grill, E. Hahnen, J. Horváth, B. Jaeger, K. Kast, M. Kiechle, E. Leinert, S. Morlot, M. Püsken, Dieter Schäfer, S. Schott, C. Schroeder, U. Siebers-Renelt, C. Solbach, N. Weber-Lassalle, I. Witzel, C. Zeder-Göss, R. Schmutzler","doi":"10.1159/000516376","DOIUrl":"https://doi.org/10.1159/000516376","url":null,"abstract":"Background: The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) has established a multigene panel (TruRisk®) for the analysis of risk genes for familial breast and ovarian cancer. Summary: An interdisciplinary team of experts from the GC-HBOC has evaluated the available data on risk modification in the presence of pathogenic mutations in these genes based on a structured literature search and through a formal consensus process. Key Messages: The goal of this work is to better assess individual disease risk and, on this basis, to derive clinical recommendations for patient counseling and care at the centers of the GC-HBOC from the initial consultation prior to genetic testing to the use of individual risk-adapted preventive/therapeutic measures.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"199 - 207"},"PeriodicalIF":2.1,"publicationDate":"2021-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000516376","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41391862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
